These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33562780)

  • 1. Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945.
    Rosales M; Rodríguez-Ulloa A; Besada V; Ramón AC; Pérez GV; Ramos Y; Guirola O; González LJ; Zettl K; Wiśniewski JR; Perera Y; Perea SE
    Cells; 2021 Feb; 10(2):. PubMed ID: 33562780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Phosphoproteomic quantification based on phosphopeptide intensity or occupancy? An evaluation based on casein kinase 2 downstream effects".
    Rodríguez-Ulloa A; Rosales M; Ramos Y; Guirola O; González LJ; Wiśniewski JR; Perera Y; Perea SE; Besada V
    J Proteomics; 2024 Sep; 307():105269. PubMed ID: 39098729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
    Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
    J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
    D'Amore C; Borgo C; Sarno S; Salvi M
    Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 Inhibition.
    Rosales M; Rodríguez-Ulloa A; Pérez GV; Besada V; Soto T; Ramos Y; González LJ; Zettl K; Wiśniewski JR; Yang K; Perera Y; Perea SE
    Front Mol Biosci; 2022; 9():834814. PubMed ID: 35359604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300.
    Rosales M; Pérez GV; Ramón AC; Cruz Y; Rodríguez-Ulloa A; Besada V; Ramos Y; Vázquez-Blomquist D; Caballero E; Aguilar D; González LJ; Zettl K; Wiśniewski JR; Yang K; Perera Y; Perea SE
    Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia.
    Klink M; Rahman MA; Song C; Dhanyamraju PK; Ehudin M; Ding Y; Steffens S; Bhadauria P; Iyer S; Aliaga C; Desai D; Huang S; Claxton D; Sharma A; Gowda C
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33807974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.
    Chon HJ; Bae KJ; Lee Y; Kim J
    Front Pharmacol; 2015; 6():70. PubMed ID: 25873900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.
    Wang S; Yadav AK; Han JY; Ahn KS; Jang BC
    Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4,5,7-Trisubstituted indeno[1,2-b]indole inhibits CK2 activity in tumor cells equivalent to CX-4945 and shows strong anti-migratory effects.
    Birus R; El-Awaad E; Ballentin L; Alchab F; Aichele D; Ettouati L; Götz C; Le Borgne M; Jose J
    FEBS Open Bio; 2022 Feb; 12(2):394-411. PubMed ID: 34873879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
    Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
    BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CK2β subunit down-regulation on Akt signalling in HK-2 renal cells.
    Alcaraz E; Vilardell J; Borgo C; Sarró E; Plana M; Marin O; Pinna LA; Bayascas JR; Meseguer A; Salvi M; Itarte E; Ruzzene M
    PLoS One; 2020; 15(1):e0227340. PubMed ID: 31910234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.
    Buontempo F; Orsini E; Martins LR; Antunes I; Lonetti A; Chiarini F; Tabellini G; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Cappellini A; Barata JT; Martelli AM
    Leukemia; 2014 Mar; 28(3):543-53. PubMed ID: 24253024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy.
    Ruggeri E; Frezzato F; Mouawad N; Pizzi M; Scarmozzino F; Capasso G; Trimarco V; Quotti Tubi L; Cellini A; Cavarretta CA; Ruocco V; Serafin A; Angotzi F; Danesin N; Manni S; Facco M; Piazza F; Trentin L; Visentin A
    Front Immunol; 2024; 15():1393485. PubMed ID: 38807597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
    Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
    Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
    Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines.
    Vázquez-Blomquist D; Ramón AC; Rosales M; Pérez GV; Rosales A; Palenzuela D; Perera Y; Perea SE
    BMC Genomics; 2023 Jul; 24(1):373. PubMed ID: 37400761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silmitasertib, a casein kinase 2 inhibitor, induces massive lipid droplet accumulation and nonapoptotic cell death in head and neck cancer cells.
    Su YW; Huang WY; Lin HC; Liao PN; Lin CY; Lin XY; Huang SH; Chen YT; Wu PS
    J Oral Pathol Med; 2023 Mar; 52(3):245-254. PubMed ID: 36273268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.